KAMADA LTD (KMDA) Form 6-K — Nov 9, 2026
Kamada reported record-high first nine months of 2026 results, with revenues of $152.2 million (up 12% YoY), adjusted EBITDA of $40.9 million (up 20% YoY), and net income of $21.4 million (up 29% YoY). Q3 net income jumped 51% YoY to $8.0 million on revenues of $52.0 million. The company raised its 2026 full-year guidance to $205-$208 million in revenues and $52-$54 million in adjusted EBITDA, mid-points representing 14% and 26% growth versus 2025, and projects double-digit growth in both revenues and profitability for 2027.
Key figures
- Eps
- Q3 2026 diluted EPS $0.14; 9M diluted EPS $0.37
- Revenue
- Q3 2026: $52.0M; 9M 2026: $152.2M
- Guidance
- 2026 revenue raised to $205M-$208M (from $200M-$205M); adjusted EBITDA raised to $52M-$54M (from $50M-$53M); projects double-digit revenue and profitability growth in 2027
- Net Income
- Q3 2026: $8.0M; 9M 2026: $21.4M
- Revenue Yoy
- Q3 +11%; 9M +12%
- Total Assets
- $382.7M
- Cash Position
- $75.3M cash, cash equivalents and short-term investments as of September 30, 2026
- Shares Outstanding
- ordinary share capital of $15,093 thousand
- Fimi ownership
- approximately 38% controlling stake
- Gross margin q3
- 45%
- Dividend per share
- $0.14 (approx. $8.0M total, payable Dec 9, 2026)
- Q3 adjusted ebitda
- $15.2M (up 30% YoY, 29% margin)
- Dividends 2026 total
- $0.56 per share / approx. $32.2M for the year
- Ninemo adjusted ebitda
- $40.9M (up 20% YoY, 27% margin)
- Operating cash flow 9m
- $37.6M (vs $17.9M year-ago)
- Plasma supply agreement
- 3-year, approximately $50M
- Biosimilar revenue projection
- approx. $10M in 2028; $20-25M by 2030
- Distribution revenue growth 9m
- +35% to $24.1M
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.